RxDoctor Payments Data

Robert Looney, DO

Internal Medicine · Starkville, MSNPI 1568807196

Payments from drug & device makers

$2,645in general payments, 2019–2025

Across 174 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$602
  • Abbott$323
  • Novo Nordisk$243
  • Lilly USA, LLC$228
  • Pfizer$226
  • GSK$186
  • plus $838 from 16 others

What the payments were for

  • Food & beverage$2,645100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,645 in reported general payments places this provider in the 75th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$91,582
Medicare patients
412
Services billed
1,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide186$197,086
FarxigaDapagliflozin Propanediol83$80,016
MounjaroTirzepatide70$73,386
JardianceEmpagliflozin51$56,733
EliquisApixaban58$55,028
LinzessLinaclotide41$31,527
Tresiba Flextouch U-200Insulin Degludec35$30,054
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$29,294
Tresiba Flextouch U-100Insulin Degludec37$26,292
XareltoRivaroxaban21$25,052
TrulicityDulaglutide11$18,441
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$17,253
EntrestoSacubitril/Valsartan19$14,528
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$9,608
Novolog FlexpenInsulin Aspart20$6,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$243$197,086186 claims
AstraZenecaFarxiga, Breztri Aerosphere$110$97,268106 claims
Lilly USA, LLCMounjaro, Trulicity$228$91,82781 claims
Boehringer IngelheimJardiance$88$56,73351 claims
PfizerEliquis$226$55,02858 claims
AbbVieLinzess, Synthroid$602$32,57959 claims
GSKTrelegy Ellipta$186$29,29437 claims
NovartisEntresto$63$14,52819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Starkville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →